Direct Screening of Clinical Specimens for Multiple Respiratory Pathogens Using the Genaco Respiratory Panels 1 and 2

Brunstein, John; Thomas, Eva

doi:10.1097/01.pdm.0000210430.35340.53

Cited by 72 publications

(63 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In efforts to move closer to more-comprehensive disease scanning and laboratory-based surveillance, a number of multiplexed assays have been developed (2,4,8,9,20,23,24,30,38,43,44,46,48). Many use a combination of techniques, such as enzyme linkage formats for detection or two or more multiplexed reactions, to obtain full coverage.…”

mentioning

confidence: 99%

Evaluation of a Multiplexed PCR Assay for Detection of Respiratory Viral Pathogens in a Public Health Laboratory Setting

Marshall¹,

Reisdorf²,

Harms³

et al. 2007

J Clin Microbiol

View full text Add to dashboard Cite

There are numerous viral and bacterial causes of respiratory disease. To enable rapid and sensitive detection of even the most prevalent causes, there is a need for more-simplified testing systems that enable researchers and clinicians to perform multiplexed molecular diagnostics quickly and easily. To this end, a new multiplexed molecular test called the MultiCode-PLx respiratory virus panel (PLx-RVP) was developed and then implemented in a public health laboratory setting. A total of 687 respiratory samples were analyzed for the presence of 17 viruses that commonly cause respiratory disease. As a comparator, the samples were also tested using a standard testing algorithm that included the use of a real-time influenza virus A and B reverse transcription-PCR test and routine viral culture identification. The standard testing algorithm identified 503 (73%) samples as positive and 184 as negative. Analyzing the same 687 samples, the PLx-RVP assay detected one or more targets in 528 (77%) samples and found 159 samples negative for all targets. There were 25 discordant results between the two systems; 14 samples were positive for viruses not routinely tested for by the Wisconsin State Laboratory of Hygiene, and 13 of these were confirmed by real-time PCR. When the results of the standard testing algorithm were considered "true positives," the PLx-RVP assay showed an overall sensitivity of 99% and an overall specificity of 87%. In total, the PLx-RVP assay detected an additional 40 viral infections, of which 11 were mixed infections.

show abstract

mentioning

confidence: 99%

Evaluation of a Multiplexed PCR Assay for Detection of Respiratory Viral Pathogens in a Public Health Laboratory Setting

Marshall¹,

Reisdorf²,

Harms³

et al. 2007

J Clin Microbiol

View full text Add to dashboard Cite

show abstract

“…The principle of tem-PCR technology was described previously (1,5,6). Conventional multiplex PCR assays are difficult to develop because of three primary problems: incompatible primer sets, high background amplification, and poor reproducibility.…”

Section: Discussionmentioning

confidence: 99%

Human Influenza A Virus (H5N1) Detection by a Novel Multiplex PCR Typing Method

et al. 2007

View full text Add to dashboard Cite

We report the use of ResPlex III for genotyping influenza A viruses. The performance characteristics of the assay with regard to H5N1 are further evaluated. The ResPlex system incorporates a novel multiplex PCR technology, target-enriched multiplex PCR, to simultaneously amplify multiple molecular targets in one reaction. The ResPlex III assay targets the H1, H2, H3, H5, H7, H9, N1, and N2 genes from the influenza A virus as well as the NS genes from influenza A (NSA) and B (NSB) viruses, providing detection and genotyping of influenza A and B viruses. The analytical sensitivities for detecting the H5, N1, and NSA genes were 1, 10 ؊1 , and 10 50% tissue culture infectious doses/200 l/reaction, respectively. A total of 217 sequential clinical samples including 14 samples with human H5N1 infections were tested by the ResPlex III assay, and the results were compared to a reference standard combined with results of viral culture and conventional reverse transcriptase and real-time PCR. The clinical sensitivity and specificity for detecting H5N1 were 93.3% and 100%, respectively, indicating that different subtypes of influenza A virus can be quickly and correctly identified using the ResPlex III genotyping approach.

show abstract

“…At present, the most successful and robust multiplexing technology is Luminex xMAP platform, which combines advanced fluidics, optics, and digital signal processing with proprietary microsphere technology to deliver multiplexed assay capabilities. Importantly, Luminex is an open technology and numerous companies have marketed the Luminex system, including Bio-Rad, Qiagen, Invitrogen, and Millipore ect.. And a steadily growing list of ready-to-use multiplexed immunoassays have also been provided by these companies for applications in biomarker discovery , autoimmune disease diagnostics [77][78][79][80] , infectious disease diagnostics [81][82][83][84][85][86][87][88][89][90][91][92][93] , neurological diseases [94][95][96][97][98][99][100][101] , HLA testing [102][103][104] , and drug discovery 105,106 ( Table 4).…”

Section: Applications Of Multiplexed Immunoassaysmentioning

confidence: 99%

“…Moreover, encoded microsphere based multiplexed immunoassay technology could improve diagnostics of infectious diseases by enabling the simultaneous detection of antibodies or antigens to multiple infectious pathogens, such as human immunodeficiency virus (HIV), the Hepatitis A, B, C virus, Mycobacterium tuberculosis, as well as a large number of other viral, bacterial and parasitic pathogens. [81][82][83][84][85][86][87][88][89][90][91][92][93] FDA-approved assays for infectious diseases (e.g. EBV, HSV, MMRV, Syphilis, and ToRC assays on BioPlex TM 2200 or Multi-Lyte TM ) are already available on market.…”

Section: Applications Of Multiplexed Immunoassaysmentioning

confidence: 99%